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cancer patients generally report greater well-being across all
domains, but age-adjusted results suggest hepatobiliary and
head/neck cancer have signiﬁcantly worse HRQL among differ-
ent types of cancer, particularly in terms of PWB and FWB.
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A COMPARISION OF THE PSYCHOMETRICS PROPERTIES OF
HEALTH RELATED QUALITY OF LIFE INSTRUMENTS USED IN
GLIOBLASTOMA MULTIFORME PATIENTS
Walthour AE, Franic DM
University of Georgia, Athens, GA, USA
OBJECTIVES: To evaluate brain cancer speciﬁc health related
quality-of-life (HRQOL) instruments used in glioblastoma mul-
tiforme (GBM) patients for group and individual level decision-
making. METHODS: An extensive literature search was
conducted to identify brain cancer speciﬁc HRQOL instruments
using several databases including Medline, PsycINFO, and
Health and Psychosocial Instruments. Key search terms included
“quality of life” and “glioblastoma”. Only brain cancer speciﬁc
HRQOL instruments evaluating GBM patients were retained for
evaluation of item information, practicality, breadth, depth, reli-
ability (group level based on Nunnally & Bernstein 1994 and
individual level based on McHorney & Tarlov 1995 criteria),
validity and responsiveness. RESULTS: Four instruments were
identiﬁed: extended Rotterdam Symptom Checklist (e-RSCL);
European Organization for Research and Treatment of Cancer
quality-of-life core 30 (EORTC QLQ C30) with brain cancer
module (BCM20); EORTC QLQ C30+3 with BCM20; and a
newly developed instrument deriving its core from the Sickness
Impact Proﬁle (SIP) with addition of a brain cancer module (BC).
The EORTC QLQ C30 was the most widely used instrument
and satisﬁed practicality, breadth and validity criteria (conver-
gent: r = 0.61–0.70, p < 0.05; known-groups: p < 0.05). This
instrument offered the most extensive reliability information
with 4 of 9 domains meeting the 0.70 criterion for group level
decision-making. The SIP core with BC was notable for high
levels of missing psychometric data. CONCLUSION: Measuring
the impact of treatment on HRQOL is critical, especially in ter-
minal conditions. However, none of the instruments in this study
met the criteria for individual level decision-making. This was
due in part to unavailable psychometric data as well as data not
meeting study criteria. Based on the results from this study, the
EORTC QLQ C30 is recommended for use in group level deci-
sion-making in conjunction with another HRQOL instrument,
for example a generic instrument. Further studies are required to
evaluate the psychometric properties of the BCM20.
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OBJECTIVES: To assess health-related quality of life (HRQOL)
in patients with metastatic renal cell carcinoma (mRCC) treated
with axitinib (AG-013736), a potent vascular endothelial growth
factor receptor inhibitor. METHODS: In a single-arm phase II
trial, mRCC patients who had received one prior cytokine-based
therapy were treated with axitinib 5 mg orally BID until disease
progression or no response (46% of patients had a PR, and 40%
had stable disease). HRQOL, a secondary endpoint, was mea-
sured using the European Organization for the Research and
Treatment of Cancer Quality of Life Questionnaire-Core 30
(EORTC-QLQ-C30). The QLQ-C30 consists of 30 questions,
rated on a 0–4 scale, measuring functional status, symptoms, and
global health. Higher scores on the functional status and global
health scales reﬂect better HRQOL, whereas higher scores on the
symptom scales indicate more severe symptoms. QLQ-C30 was
completed at baseline, monthly for the ﬁrst two cycles, every 2
cycles thereafter, and at follow-up. Longitudinal analyses were
used to evaluate HRQOL data through 36 cycles of treatment.
RESULTS: Fifty-four patients completed baseline HRQOL
assessments. Statistically signiﬁcant changes (P < 0.05) were
observed in average scores from baseline to post-treatment in the
role, cognitive and social functioning scales, and the nausea/vom-
iting, pain and diarrhea symptoms. These changes were approx-
imately <1/4 of a response category. The exception was diarrhea,
with a 1/2 category change, which equated to a change from
“no” to “a little” diarrhea. CONCLUSION: Although some
measures of functioning and symptoms are statistically signiﬁ-
cant, interpretation of QLQ-C30 scores from the current litera-
ture (King 1996 Qual Life Res; Osoba 1998 JCO) indicate that
changes observed in the study are, overall, too small to reﬂect a
palpable change in patient functioning and symptoms. Thus,
treatment with axitinib demonstrated minimal disruptions in
HRQOL compared to baseline levels in mRCC patients.
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OBJECTIVES: HUI is a family of multi-attribute, health-status
classiﬁcation and preference scoring systems for general popula-
tion health surveys and clinical research studies including cost-
utility economic evaluations of alternative treatments. It has been
translated and culturally adapted into many languages. This is
the ﬁrst report of HUI in Turkish. METHODS: The original
English-language health-status classiﬁcation system was trans-
lated into Turkish by 3 physicians from the pediatric oncology
clinic in Istanbul. The consensus forward translation was inde-
pendently back translated and then reviewed by HUInc staff. It
provides the keywords for subsequent HUI questionnaire trans-
lation. The same forward/backward translation strategy with 
all-party consensus produced the interviewer-administered 
questionnaire for proxy assessments (HUI23P1Tr.40Q). The
questionnaire was evaluated for acceptability and construct
validity by interviewing parents of patients who developed neu-
tropenia during their ﬁrst chemotherapy cycle. Parents were
interviewed twice at the Istanbul clinic, during and again after
the neutropenic episode. Upon completion of the ﬁrst interview,
parents were asked informally about the questionnaire readabil-
ity and suitability. Utility scores are from the original published
functions based on general population preference measurements
and differences in mean utility scores were tested using ANOVA.
RESULTS: Parents of 50 newly diagnosed patients (26 males,
mean age 91.3 months) were interviewed. The questionnaire was
reported by all parents to be understandable and acceptable.
Overall utility scores of health-related quality of life (HRQL)
during neutropenic episodes (HUI2 mean = 0.65, SD = 0.251;
HUI3 mean = 0.60, SD = 0.328) were signiﬁcantly and impor-
tantly lower (HUI2 p = 0.008, HUI3 p = 0.034) than after recov-
ery (HUI2 mean = 0.79, SD = 0.244; HUI3 mean = 0.75, SD =
0.315) as were the single-attribute scores for HUI2 and HUI3
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emotion (p = 0.048, p = 0.015). CONCLUSION: As expected,
the patients had lower HRQL and increased emotional morbid-
ity when neutropenic. Parental reports provide evidence that the
Turkish translation is acceptable, understandable and has con-
struct validity for assessing health-status in childhood cancer
patients.
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OBJECTIVES: The functional status of individuals and their self-
rated quality of life has been shown to be an important predic-
tor of general quality of life, mortality, and utilization of health
services. We investigated the factors associated with physical
function (PF) and general health (GH) at baseline in patients with
prostate cancer as well as factors associated with changes over
the course of disease. METHODS: Data from CaPSURE, a lon-
gitudinal disease registry of men with prostate cancer, was used
to identify a group of men who were newly diagnosed with
prostate cancer, have deﬁned initial treatment, and had one pre-
treatment and at least two years of post-treatment HRQOL
assessments. HRQOL were measured by SF-36 and were
assessed bi-annually. Changes in PF and GH scores over time
were evaluated by mixed model analysis, accounting for type of
treatment received, time of HRQOL assessment, age at diagno-
sis, level of function at baseline, and education level. RESULTS:
3625 patients met the study criteria. At baseline high level of
physical functioning and general health (median 95 and 75
respectively) were demonstrated. In multivariate mixed model
analysis type of treatment, baseline level of physical function,
time of HRQOL assessment, age, education level, and interac-
tion term between time and type of treatment were signiﬁcantly
associated with changes in PF and GH over time. Differences in
PF and GH persisted through the period of study and varied
greatly depending on level of function at baseline (adjusted
means 62.7 vs. 95.2 for PF and 62.1 vs. 78.0 for GH at ﬁrst year
after treatment). CONCLUSION: Further evaluation of the rela-
tionship between GH and PF can provide us with important
information to identify critical elements of HRQOL. Identiﬁca-
tion of the speciﬁc determinants of perceived and objective
measure could provide us with tools for improving overall
quality of life in patients with prostate cancer.
PCN57
PATIENT REPORTED OUTCOMES IN LABELING FOR
ONCOLOGY PRODUCTS: REVIEW OF FDA AND 
EMEA LABELS
Caron M1, Emery MP1, Marquis P2, Piault E2
1Mapi Research Trust, Lyon, France, 2Mapi Values, Boston, MA, USA
OBJECTIVES: To review the oncology products approved in the
United States and in Europe with a particular focus on the
Patient-Reported Outcome (PRO) end-points appearing in the
products’ labels. METHODS: Oncology products approved in
Europe since 1995 through the centralized procedure and in the
United States since 1998 (new molecular entities) were identiﬁed
directly from our internal resources resulting from a review of
the EMEA and FDA websites. Using the PROLabels database,
we identiﬁed the products indicated for cancer treatment and
showing evidence of PRO in labeling. PRO Labels is a unique
on-line tool which provides information on the drug products
for which the FDA and/or the EMEA have granted a PRO label-
ing claim RESULTS: Overall, 36 different products indicated for
the treatment of cancer were identiﬁed in this review, 12 of which
were approved both in Europe and in the U.S. Of these 36
approved drugs, 7 contained descriptions of Patient-Reported
Outcomes in the labeling. Two drugs were approved in the US
with PRO data used to assess health-related quality of life
(HRQL), treatment satisfaction and subjective assessment of
lesions. In Europe, 5 products used PRO data to capture HRQL,
pain, and symptoms. These products were different from the US
ones. Regarding the methods to measure PRO, 5 products used
a deﬁned instrument, one used a single item and another used a
questionnaire which was not speciﬁed. CONCLUSION: Overall,
PRO data in labeling for oncology products is not frequent
(between 8 and 20% of approved products), and is comparable
with the average rate over all therapeutic areas (source PROLa-
bels). The location of PRO endpoints was mainly in the clinical
studies section. An interesting ﬁnding is the lack of overlap
between the American and the European PRO claims.
EAR/EYE—Clinical Outcomes Studies
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OBJECTIVES: The objective of this study was to compare
ciproﬂoxacin 0.3%/dexamethasone 0.1% (CD) otic suspension
to polymyxin B/neomycin/hydrocortisone (PNH) otic suspension
for the treatment of acute otitis externa (AOE). METHODS:
Data from two randomized AOE clinical trials were pooled
together for this analysis. AOE patients randomly received either
CD, 3–4 drops twice a day for seven days, or PNH, 3–4 drops
three times a day for seven days. Clinical assessment of ear
inﬂammation, ear tenderness, ear edema and ear discharge were
performed on days 3, 8 and 18 of the study. Inﬂammation and
edema were evaluated using the following four point scale: none
= 0, mild = 1, moderate = 2, severe = 3. Ear tenderness and otic
discharge were rated on a scale where absent = 0 and present =
1. A composite clinical score with a range of 0 to 8 was used as
the ﬁnal outcomes measure. Clinical cure was deﬁned as com-
posite clinical score of zero. A Kaplan-Meier survival analysis
with a log-rank test was used to compare the cure rates between
treatment groups. RESULTS: A total of 1072 patients (1242
ears) were included in the analysis (537 CD patients and 535
PNH patients). Both treatment groups were similar with respect
to baseline AOE severity and demographic parameters. The log-
rank test revealed a signiﬁcant (p = 0.0380) difference in AOE
cure rates between the CD and PNH groups. The Kaplan-Meier
analysis indicated that CD patients were cured 0.6 days sooner
than PNH patients (9.7 versus 10.3 days, respectively) and the
time needed to cure 75% of the CD group was 8 days compared
to 18 days for the PNH group. CONCLUSION: CD appears to
be superior to PNH for the treatment of AOE due to its faster
cure rate.
